文献速递贫血与红细胞疾病

血红蛋白H病所致α地中海贫血的疾病负担、管理策略与未满足需求

Disease burden, management strategies, and unmet needs in α-thalassemia due to hemoglobin H disease.
PubMed 文献 · Am J Hematol · 2024-07-22

本文综述血红蛋白H(HbH)病的病理生理、当前管理策略、未满足需求及新兴治疗选择。HbH病由累及四个α珠蛋白等位基因中三个表达的突变组合引起,疾病严重程度高度异质,主要由基因型决定。非缺失型突变较缺失型突变导致更严重的无效造血和溶血、更高的输血负担及并发症风险。

要点

  • HbH病由累及四个α珠蛋白等位基因中三个表达的突变组合引起
  • 疾病严重程度高度异质,主要由基因型决定
  • 非缺失型突变较缺失型突变导致更严重的无效造血、溶血、更高输血负担及并发症风险

核心结论

  • HbH病治疗选择有限,需要有效疗法。

研究设计与样本

  • 综述,讨论HbH病的病理生理、当前管理策略、未满足需求及新兴治疗选择。

主要发现

  • α地中海贫血是由α珠蛋白链生成受损引起的遗传性血液病,导致贫血及其他并发症。
  • HbH病由累及四个α珠蛋白等位基因中三个表达的突变组合引起,疾病严重程度高度异质,主要由基因型决定。
  • 非缺失型突变较缺失型突变导致更严重的无效造血和溶血、更高的输血负担及增加的并发症风险。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Alpha-thalassemia is an inherited blood disorder caused by impaired α-globin chain production, leading to anemia and other complications. Hemoglobin H (HbH) disease is caused by a combination of mutations generally affecting the expression of three of four α-globin alleles; disease severity is highly heterogeneous, largely driven by genotype. Notably, non-deletional mutations cause a greater degree of ineffective erythropoiesis and hemolysis, higher transfusion burden, and increased complication risks versus deletional mutations. There are limited treatment options for HbH disease, and effective therapies are needed. This review discusses the pathophysiology of HbH disease, current management strategies, unmet needs, and emerging treatment options.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Lal A, Viprakasit V, Vichinsky E, et al. Disease burden, management strategies, and unmet needs in α-thalassemia due to hemoglobin H disease. Am J Hematol. 2024. PMID: 39037279. doi:10.1002/ajh.27440

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。